Takeda Oncology

Many people with metastatic colorectal cancer (#mCRC) reported feeling overwhelmed by the information they received at diagnosis. We partnered with BLKHLTH, Colorectal Cancer Alliance, Family Reach and COLONTOWN to conduct a U.S. patient survey to understand lived experiences and turn complex information into clearer, more actionable insights. These insights can help us address unmet needs throughout the mCRC journey. Read the full results of the U.S. patient survey for more findings: https://lnkd.in/g56a5sjy

We are pleased to share that the full data from our U.S. metastatic colorectal cancer (mCRC) patient survey, conducted in partnership with BLKHLTH, Colorectal Cancer Alliance, Family Reach, and COLONTOWN, has been published in Future Oncology.  These findings highlight opportunities to address delays in diagnosis, the impact of mCRC on quality of life, and how cultural factors can influence care and strengthen connections to advocacy. Read the publication here: https://lnkd.in/g56a5sjy

While phlebotomy is one of the current standards of care for polycythemia vera (PV), it can contribute to iron deficiency, cause or worsen certain symptoms and lead to a burden on patients’ quality of life. In a recent conversation, Takeda’s Teresa Bitetti Unit, and Kapila Viges, CEO of the MPN Research Foundation, discuss the phlebotomy experience and why continued progress in PV care is so important.    Watch the full video here: https://lnkd.in/gXqgKiVM

Some mornings are “let’s do this.” Others are “not today.” For Patti, that unpredictability is part of living with polycythemia vera (PV). Extreme fatigue and aches can affect her energy, her routine and what she’s able to take on – even when symptoms aren’t always visible to others. Blood Cancer Awareness Month is an opportunity to bring attention to the experiences that often go unseen. Hear Patti’s experience living with PV: https://lnkd.in/gbHQtDtQ

This month, #TeamTakeda wore red in recognition of Blood Cancer Awareness Month and Myeloproliferative Neoplasms Awareness Day.    People living with blood cancers inspire our commitment to advancing science and supporting patients throughout their cancer journey. We’re proud to stand alongside the blood cancer community this month and every day.

#TeamTakeda is headed to Madrid for #ESMO26, taking place Oct. 23-27, where we’re sharing new data for our oncology portfolio and pipeline. Our presence at ESMO - European Society for Medical Oncology reflects the momentum of our late-stage pipeline and our continued commitment to patients living with thoracic and gastrointestinal cancers. Discover more about our research at ESMO: https://lnkd.in/g7h-2twP

The experience for each person living with polycythemia vera (PV) is unique. The spectrum of symptoms can vary widely from patient to patient with this blood cancer, making the path to diagnosis difficult and the patient journey feel isolating.   In this conversation, Takeda’s Teresa Bitetti, President, Global Oncology Business Unit, and MPN Research Foundation's CEO, Kapila Viges, discuss the clinical complexity and symptom variability of PV.   Watch the full video: https://lnkd.in/gXqgKiVM

Patti shares her experience navigating life with polycythemia vera (PV), including the uncertainty, perspective shifts and resilience that have shaped her journey. Her story is a reminder that strength isn’t about pushing for perfection. Sometimes it’s simply choosing to move forward despite setbacks: https://lnkd.in/eTVq9W43

For too long, people living with #PolycythemiaVera (#PV) have had limited treatment options. Now, new advances are contributing to meaningful progress. The recent FDA approval of a new treatment for erythrocytosis in adults with PV is the result of years of clinical advancement and partnership. Hear from Teresa Bitetti, President of Takeda’s Global Oncology Business Unit, on the significance of this moment and what it could mean for people living with PV.

Today marks an important milestone for the polycythemia vera (PV) community. We are grateful to the patients, care partners, advocates and investigators who helped make this approval possible. Read more: https://lnkd.in/gbc4yZkY